Showing results (1-10 of 201) with videos related to
Sort By:
Pageof 21
Expert Opinion on Biological Therapy|March 5, 2013
Canakinumab in pediatric rheumatic diseasesNico M Wulffraat, Patricia WooExpert Opinion on Drug Safety|November 17, 2015
A safety evaluation of canakinumab for the treatment of systemic onset juvenile idiopathic arthritisNico M WulffraatThe Israel Medical Association Journal : IMAJ|October 14, 2008
Diagnostic workup for mixed connective tissue disease in childhoodJoost F Swart, Nico M WulffraatExpert Review of Clinical Immunology|May 27, 2014
Methotrexate in juvenile idiopathic arthritis: towards tailor-made treatmentMaja Bulatović Ćalasan, Nico M WulffraatCurrent Rheumatology Reports|May 31, 2015
Vaccinations in paediatric rheumatology: an update on current developmentsNoortje Groot, Marloes W Heijstek, Nico M WulffraatPediatric Rheumatology Online Journal|December 20, 2014
Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature reviewE H Pieter van Dijkhuizen, Nico M WulffraatAnnals of the Rheumatic Diseases|June 26, 2014
Early predictors of prognosis in juvenile idiopathic arthritis: a systematic literature reviewE H Pieter van Dijkhuizen, Nico M WulffraatExpert Reviews in Molecular Medicine|November 17, 2006
Refractory juvenile idiopathic arthritis: using autologous stem cell transplantation as a treatment strategyNico M Wulffraat, Ismé M de Kleer, Berent PrakkenArthritis Research & Therapy|June 5, 2013
What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?Joost F Swart, Sytze de Roock, Nico M WulffraatPageof 21